Press Release

Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.

Global Cloning and Mutagenesis Market to Grow at a CAGR of 17% During 2022-2027, Aided by the Rising Prevalence of Chronic and Genetic Diseases

According to a new report by EMR titled, ‘Global Cloning and Mutagenesis Market Report and Forecast 2022-2027’, the global market for cloning and mutagenesis is expected to grow at a CAGR of 17% in the forecast period of 2022-2027.

With the growing prevalence of various genetic and chronic diseases, cloning of genes is extensively used in the detection of such issues and in their treatment through methods like gene therapy. Hence, the rising cases of sickle cell anaemia and leukaemia, among others, are driving the cloning and mutagenesis market.

 

The increasing cloning of genes in the synthesis of antibiotics, hormones, and vitamins, among others, for the treatment of issues such as cystic fibrosis is propelling the market growth. The market growth can also be attributed to the rising use of cloning in supporting new discoveries for therapeutics, vaccine development, and various emerging synthetic biology applications. Furthermore, the increasing research activities to develop next-generation cloning for creating custom vectors for any application are likely to fuel the market growth.

 

The addition of cloning in various advanced systems by the leading companies is propelling the cloning and mutagenesis market. In May 2021, Codex DNA, Inc. (NASDAQ: DNAY) announced the addition of a longer fragment cloning to its BioXp™ system, which is a fully automated benchtop instrument facilitating various synthetic biology workflows. It would eliminate the requirement to manually synthesise error-corrected genes. 

 

The addition of longer fragment cloning would also enable scientists to produce multivariant, error-corrected, de novo synthetic genes up to 7.2 kilobase pairs (kb) in length. The cloning of them into custom vectors could be done overnight and hands-free by using the company’s Gibson Assembly technology. 

 

Moreover, the 7.2 kb length expands the use of the BioXp™ system to enable researchers to study proteins larger than human proteins. This would also boost the use of the system in various applications such as metabolic engineering, antibody engineering, small genome construction, and targeted gene variant analysis, among others.

 

Market Analysis by Product, Technique, End Use, and Region:

  • The cloning and mutagenesis market, on the basis of product, can be divided into cloning kits and mutagenesis kits.
  • Based on technique, the market can be divided into topo PCR cloning, blunt end cloning, seamless cloning, and site-directed mutagenesis, among others.
  • The major end uses of cloning and mutagenesis include biotechnology companies and academic and research institutes, among others.
  • The regional markets for cloning and mutagenesis include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

 

Key Findings of the Report:

  • The growing prevalence of various genetic and chronic diseases and the rising demand for personalised medicines are augmenting the cloning and mutagenesis market growth.
  • The market is being propelled by the rising investments in research and development activities for the treatment of genetic diseases.
  • The robust growth of the biotechnology industry, the surging funding by various governmental organisations, and the advancements in cloning and mutagenesis technology are driving the market growth of cloning and mutagenesis.
  • The increasing cost-effectiveness of cloning and mutagenesis kits is invigorating the market growth.

 

Key Offerings of the Report: 

  • The EMR report gives an overview of the global cloning and mutagenesis market for the periods (2017-2021) and (2022-2027).
  • The report also offers the historical (2017-2021) and forecast (2022-2027) markets for the products, techniques, end uses, and major regions of cloning and mutagenesis.
  • The report analyses the market dynamics, covering the key demand and price indicators in the market, along with an assessment of the SWOT and Porter’s Five Forces models.

 

The major players in the global cloning and mutagenesis market are Thermo Fisher Scientific Inc., Takara Bio Inc., Codex DNA, Inc., Agilent Technologies, Inc., and TransGen Biotech Co., Ltd., among others. The comprehensive report by EMR looks into the market share, capacity, and latest developments like mergers and acquisitions, plant turnarounds, and capacity expansions of the major players.

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER